3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Colorectal Neoplasms
3
Breast Neoplasms
3
Stomatitis
2
Neoplasms
2
Mucositis
2
Vulvodynia
1
Urologic Neoplasms
1
Urologic Diseases
1
Urolithiasis
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Pain, Postoperative
1
Pain
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 1
1
Mobility Limitation
1
MRSA Colonization
1
Lymphoma
1
Leukemia
1
Ilues
1
Hydronephrosis
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Dyspareunia
1
Disease
1
Interventions
Gemcitabine
79
Cisplatin
56
pembrolizumab
32
Paclitaxel
28
Carboplatin
24
Docetaxel
19
Radiotherapy
17
Mitomycin
16
Doxorubicin
15
atezolizumab
14
BCG Vaccine
14
Nivolumab
13
Cystectomy
13
Filgrastim
11
vinflunine
10
Methotrexate
10
Vinblastine
9
Fluorouracil
9
5-aminolevulinic acid hexyl ester
9
Sunitinib
7
Early Intervention, Educational
7
durvalumab
6
avelumab
6
Taxes
6
Methods
6
Cystoscopy
6
Albumin-Bound Paclitaxel
6
enfortumab vedotin
5
Trastuzumab
5
Surveys and Questionnaires
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Urinary Bladder Neoplasms
×
Water
×
Clear all
NCT01803295
2017-06-16
OPTIMA
UroGen Pharma Ltd.
Phase NA
Completed
80 enrolled